Effects of oxiracetam combined with ginkgo biloba extract in the treatment of acute intracerebral hemorrhage: A clinical study

Abstract

Purpose The present clinical study was conducted to investigate the effect of oxiracetam combined with ginkgo biloba extract in treating patients with acute intracerebral hemorrhage. Methods Ninety‐eight patients with acute cerebral hemorrhage admitted to our hospital were divided into three groups. The differences of brain edema and cerebral hemorrhage were compared between the three groups after 1 and 2 weeks of treatment, and the recovery of neurological function, serum inflammatory factors, AQP‐4, MMP‐9, cognitive function, activities of daily living, and adverse reactions were compared between the three groups after 2 weeks of treatment. Results There was no significant difference among the three groups before treatment ( p > .05). After treatment, the recovery of neurological function, serum inflammatory factors, AQP‐4, MMP‐9 levels, cognitive function, and activities of daily living were improved. Among them, the neurological function recovery, serum inflammatory factors, AQP‐4, MMP‐9 levels, cognitive function, and activities of daily living in the combined treatment group and the control group elicited greater results than those in the routine group. The results of the combined treatment group showed the most significant difference ( p < .05). The concentration of IL‐6 decreased from 135.98 ± 12.54 to 91.83 ± 7.69 pg/ml, AQP‐4 from 227.55 μg/L ± 21.06 to 114.31 ± 9.22 μg/L, and MMP‐9 from 172.39 ± 9.81 to 94.98 ± 5.01 ng/ml. In addition, the neurological function recovery, the levels of serum inflammatory factors, cognitive function, and activities of daily living in the combined treatment group were better than those in the control group ( p < .05). The mean score of MRS in the combined treatment group decreased from 3.36 ± 0.98 at admission to 1.91 ± 0.38. Conclusion Oxiracetam combined with Ginkgo biloba extract in the treatment of acute cerebral hemorrhage has a significant improvement effect.

Beneficial effects of Ginkgo biloba leaf extract on inflammatory markers: A systematic review and meta‐analysis of the clinical trials

“…The characteristics of the included studies are illustrated in Table 1. These studies were published between 2005 and 2020 and were from the Iraq (Abu‐Raghif, Ali, Farhood, Hameed, & Sahib, 2013; Aziz, Hussain, Mahwi, & Ahmed, 2018; Ismael & Othman, 2013; Thanoon, Abdul‐Jabbar, & Taha, 2012), China (Aishuang, Wang, Zhao, & Wang, 2014; Chun‐pu, 2010; Fang et al, 2018; Huang, Li, & Liu, 2008; P. Li, 2012; X. X. Li, Liu, Zhuang, Guo, & Pang, 2020; Wang, Qin, Xu, & Xu, 2017; Wu, Huang, & Wang, 2012; Xia et al, 2020; Yun et al, 2005; ZhiQiang, XiaoLi, & YunFen, 2012; Jianhui, 2011) and Korea (Kim et al, 2005) with 567 participants in the GB group and 537 in the control group. All studies were performed on both genders.…”

“…All studies were conducted in a similar design. Trials were performed on patients with knee osteoarthritis (Ismael & Othman, 2013), cerebral infarction (Wang et al, 2017), vitiligo (Abu‐Raghif et al, 2013), acute intra‐cerebral hemorrhage (Li et al, 2020), arsenicosis (Xia et al, 2020), end‐stage renal disease (Kim et al, 2005), acute ischemic colitis (Fang et al, 2018), metabolic syndrome (Aziz et al, 2018), severe acute pancreatitis (ZhiQiang et al, 2012), coal‐burning arsenic (Yun et al, 2005), diabetic nephropathy (Chun‐pu, 2010), chronic obstructive pulmonary disease (Li, 2012), acute respiratory distress syndrome (Wu et al, 2012), chronic hepatitis B (Jianhui, 2011), cerebrovascular accident (Thanoon et al, 2012), and asthma (Aishuang et al, 2014). According to the Cochrane Risk of Bias Assessment Tool, one study (Thanoon et al, 2012) considered as a high‐quality study with a low risk of bias for all domains, two studies (Aishuang et al, 2014; Wu et al, 2012) were of moderate‐quality since one or more domains had an unclear risk of bias and others had low quality because in one or more domains, they had a high risk of bias (Table 2).…”